Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

AIThority Predictions Series 2024 bannerThe agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

Recommended AI News: Kinara Forms Collaborations with Ampere and Mirasys to Drive Widespread Adoption of AI Solutions

Related Posts
1 of 39,481

“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.

ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.

Recommended AI News: DataCore Software Unveils Next-Gen Capabilities in SANsymphony and Swarm Storage Offerings

“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.